透析导管相关血流感染:ClearGuard HD抗菌屏障帽的整群随机试验
这项为期12个月的前瞻性、整群随机、多中心、开放标签试验纳入40家透析中心的2470例使用中心静脉导管的血液透析患者,比较ClearGuard HD抗菌屏障帽与标准导管帽对阳性血培养率的影响。结果显示,使用ClearGuard HD帽12个月与标准帽相比,血流感染率降低56%(0.26 vs 0.59/1000导管日,P=0.01),持续使用后6个月降低69%(0.22 vs 0.72/1000导管日,P=0.01),且未报告器械相关不良事件。
要点
- 使用ClearGuard HD抗菌屏障帽12个月,血流感染率较标准帽降低56%(0.26 vs 0.59/1000导管日,P=0.01)。
- 持续使用(试验后6个月)时,血流感染率降低69%(0.22 vs 0.72/1000导管日,P=0.01)。
- 持续使用时,血流感染住院率减少43%(0.28 vs 0.48/1000导管日,P=0.04),住院天数减少51%(2.42 vs 4.94/1000导管日,P=0.04)。
核心结论
- 与标准中心静脉导管帽相比,使用ClearGuard HD抗菌屏障帽可显著降低使用中心静脉导管的血液透析患者的导管相关血流感染率和血流感染住院率。
研究设计与样本
- 12个月、前瞻性、整群随机、多中心、开放标签试验;40家Fresenius Medical Care North America透析中心按阳性血培养率和中心静脉导管患者数配对后整群随机,每组20家;共2470例患者(干预组1245例,对照组1225例),累计约350000个导管日。
主要发现
- 基线阳性血培养率两组相似(P=0.8)。
- 使用ClearGuard HD帽12个月,血流感染率为0.26 vs 标准帽0.59/1000导管日,降低56%(P=0.01)。
- 持续使用(定义为研究最后6个月)时,血流感染率为0.22 vs 0.72/1000导管日,降低69%(P=0.01)。
- 持续使用时,血流感染住院率为0.28 vs 0.48/1000导管日,减少43%(P=0.04);血流感染住院天数为2.42 vs 4.94/1000导管日,减少51%(P=0.04)。
- 未报告器械相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为开放标签;患者偶尔在非研究机构接受血液透析;患者住院期间未接受干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rate of bloodstream infections (BSIs) is disproportionately high in hemodialysis (HD) patients with central venous catheters (CVCs) versus those with permanent accesses, contributing to poorer outcomes, such as increased rates of death and hospitalizations. STUDY DESIGN: 12-month, prospective, cluster-randomized, multicenter, open-label trial. SETTING & PARTICIPANTS: 40 Fresenius Medical Care North America dialysis facilities were matched and paired by positive blood culture rate and number of patients with CVCs and then cluster-randomized with 20 in each study group. 2,470 patients participated in the study (1,245, intervention group; 1,225, control group), accruing approximately 350,000 CVC-days. INTERVENTION: Use of ClearGuard HD Antimicrobial Barrier Caps versus use of standard CVC caps; assigned at the facility level. OUTCOME: Primary end point was positive blood culture rate as an indicator of BSI rate. MEASUREMENTS: Positive blood cultures, hospital admissions for BSI, hospitalization-days for BSI, intravenous antibiotic starts, and CVC-days. RESULTS: Baseline positive blood culture rates were similar (P=0.8) between groups. Use of ClearGuard HD caps for 12 months was associated with a 56% lower BSI rate versus use of standard CVC caps (0.26 vs 0.59/1,000 CVC-days, respectively; P=0.01). When considering sustained use (defined as last 6 months of the study), the intervention versus the control was associated with a 69% lower BSI rate (0.22 vs 0.72/1,000 CVC-days, respectively; P=0.01), 43% fewer hospital admissions for BSI (0.28 vs 0.48/1,000 CVC-days, respectively; P=0.04), and 51% fewer hospitalization days for BSI (2.42 vs 4.94/1,000 CVC-days, respectively; P=0.04). No device-related adverse events were reported. LIMITATIONS: Study was open label; patients occasionally received HD at nonresearch facilities; patients did not receive the intervention when hospitalized. CONCLUSIONS: The findings show that use of ClearGuard HD Antimicrobial Barrier Caps, when compared with standard CVC caps, significantly lowers rates of catheter-related BSIs and hospital admissions for BSI in HD patients using CVCs.
引用
- Hymes JL, Mooney A, Van Zandt C, et al. Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap. Am J Kidney Dis. 2016. PMID: 27839894. doi:10.1053/j.ajkd.2016.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。